SG Americas Securities LLC Has $64,000 Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

SG Americas Securities LLC increased its stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 254.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,849 shares of the company’s stock after purchasing an additional 30,037 shares during the period. SG Americas Securities LLC’s holdings in Atossa Therapeutics were worth $64,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ATOS. XTX Topco Ltd acquired a new position in Atossa Therapeutics in the second quarter valued at about $29,000. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics in the 1st quarter valued at about $72,000. Virtu Financial LLC acquired a new stake in shares of Atossa Therapeutics in the 1st quarter valued at approximately $151,000. Rhumbline Advisers acquired a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at approximately $161,000. Finally, Bank of New York Mellon Corp grew its holdings in Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the period. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Stock Performance

Shares of ATOS opened at $1.45 on Tuesday. The firm’s 50 day moving average price is $1.42 and its two-hundred day moving average price is $1.38. Atossa Therapeutics, Inc. has a twelve month low of $0.62 and a twelve month high of $2.31. The firm has a market cap of $182.35 million, a P/E ratio of -6.04 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOS) last announced its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, sell-side analysts anticipate that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ATOS. Ascendiant Capital Markets increased their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a report on Wednesday, September 11th. StockNews.com raised Atossa Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Atossa Therapeutics in a research note on Monday, August 12th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.